-
Evaluate REC-4881 In Patients With FAP (TUPELO)
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this trial is to designed to characterize the safety, tolerability, PK, PD, and preliminary activity of REC-4881 administered orally (PO) at multiple doses on a once daily schedule in participants with phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site.
-
A Study to Review the Safety of Familial Adenomatous Polyposis/Erlotinib Study
Scottsdale/Phoenix, AZ
The purpose of this study is to review clinical endoscopy reports, pathology reports, and other medical records related to standard-of-care endoscopic evaluations for all participants in the parent study, MAY2016-07-01, who provide consent for the review of their medical records. There have been reports of rapid progression of recurrent polyps after completion intervention and follow up under the parent protocol. A review of literature found insufficient data to determine whether or not there is a longer term safety risk to the participant in MAY2016-07-01.
-
A Study To Evaluate Encapsulated Rapamycin To Prevent Progression Of Familial Adenomatous Polyposis In Patients
Scottsdale/Phoenix, AZ
The purposes of this study are to analyze the frequency and severity of adverse events associated with low-dose encapsulated rapamycin in Familial Adenomatous Polyposis (FAP), to determine the recommended phase 2 dose (RP2D) based on assessment of safety, long-term tolerability, optimal blood levels, and clinical benefit, and to determine the effectiveness of eRapa in delaying polyp progression in patients with FAP compared to historic controls.
-
A Database to Monitor Outcomes and Function Following Ileal Pouch Anal Anastomosis
Rochester, MN
The purpose of this study is to analyze patient outcomes after ileal pouch anal anastomosis.
-
A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis
Scottsdale/Phoenix, AZ; Jacksonville, FL
This is a proof-of-concept study to evaluate the preliminary clinical activity of guselkumab in subjects with Familial Adenomatous Polyposis. The study is designed to determine if guselkumab has clinical activity in the colorectum and duodenum, by reducing the number of polyps over a period of 24 weeks.
-
Return Of Actionable Variants Empirical
Rochester, MN
The purpose of this study is to conduct a genomic medicine implementation project to establish mechanisms for return of actionable findings from targeted sequencing of ~109 disease-relevant genes and genotyping of select polymorphisms in a large study setting (eMERGE III consortium). A primary focus of the Mayo group will be on two common actionable genetic disorders–familial hyperlipidemia (FH) and familial colorectal cancer (CRC).